Chronic Recurrent Multifocal Osteomyelitis
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone disorder characterized by recurrent episodes of bone pain, inflammation, and multifocal osteomyelitis. As a professional CRO in the field of autoimmune diseases research, our company is dedicated to advancing the understanding and therapeutics of CRMO through innovative drug and therapy development services.
Introduction to Chronic Recurrent Multifocal Osteomyelitis
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory disease that primarily affects the bones, leading to recurrent episodes of bone pain, inflammation, and multifocal osteomyelitis. Genetic studies have identified associations between CRMO and certain genes involved in immune regulation, such as the IL1RN gene encoding the interleukin-1 receptor antagonist. Dysregulation of the IL-1 pathway is believed to play a critical role in the pathogenesis of CRMO. Imbalances in pro-inflammatory and anti-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10), have also been observed in CRMO cases. These imbalances contribute to chronic inflammation and bone destruction seen in the disease.
Fig.1 Molecular pathomechanisms in Chronic non-bacterial osteomyelitis (CNO)/Chronic Recurrent Multifocal Osteomyelitis (CRMO). (Singhal S., et al., 2023)
Drug Discovery and Development for Chronic Recurrent Multifocal Osteomyelitis
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as the initial therapeutics for CRMO cases that do not involve the vertebral column. They are effective in providing rapid relief from symptoms and effectively controlling bone inflammation in many cases. Corticosteroids, such as prednisone, may be used as short-term courses or low-dose "bridging therapy" in combination with disease-modifying anti-rheumatic drugs (DMARDs). While corticosteroids can quickly control bone inflammation in most cases, they are not effective in achieving long-term remission. Additionally, bisphosphonates, particularly pamidronate, have shown promising results in inducing both rapid and long-lasting remission in the majority of CRMO cases.
At our company, we are dedicated to delivering innovative drug and therapeutic development services that cater to the specific needs of our clients. To explore the diverse range of therapy development services we offer, please follow the link provided below.
Our Services
As a leading company specializing in pharmaceutical research and autoimmune diseases, our company offers comprehensive diagnostics and therapy development services for chronic recurrent multifocal osteomyelitis (CRMO). Our animal models replicate the key features of CRMO, including bone lesions, inflammation, and immune dysregulation. By studying these models, we can elucidate the underlying mechanisms driving CRMO and evaluate the efficacy and safety of potential drug candidates.
- Pstpip2cmo Model Development
We provide the Pstpip2cmo mouse model as an effective tool to study CRMO. This model carries a missense mutation in the Pstpip2 gene, resulting in an autoinflammatory disease similar to CRMO in humans. Pstpip2 encodes a proline-serine-threonine phosphatase-interacting protein 2, which regulates membrane and cytoskeletal dynamics.
The Pstpip2cmo model provides an opportunity to investigate the roles of NLRP3/caspase-1 and caspase-8 pathways, which have been implicated in CRMO. Additionally, this model allows for the study of caspase-8, known primarily for driving death receptor–driven extrinsic apoptosis, and its potential involvement in IL-1β processing.
- LPIN2 Mutation Model Development
By utilizing state-of-the-art genetic engineering techniques, we can introduce specific LPIN2 mutations into animal models, replicating the genetic alterations observed in Majeed syndrome. These models allow researchers to investigate the effects of LPIN2 mutations on immune cell function, inflammatory responses, and bone remodeling processes.
- Cell-Based Model Development
Our company offers tailored cell line-based CRMO model development services to researchers. These models involve the use of established cell lines, such as osteoblasts, osteoclasts, and immune cells, to mimic the interactions between different cell types involved in CRMO. - Organoid Model Development
Organoids are self-organized structures derived from stem cells or primary cells, capable of recapitulating the complex architecture and cellular interactions found in tissues. Our company offers cutting-edge 3D organoid model development services, allowing researchers to investigate CRMO in a more accurate and sophisticated manner.
Our Advantages
Time-saving services with high efficiency
Fast and cost-efficient workflow
Timely project reporting and after-sales service
Professional and experienced multidisciplinary experts
Careful design and transparent operation process
Superior data quality and fast turnaround
By employing advanced technologies and adhering to strict quality standards, we ensure that our preclinical research accurately reflects the potential of novel therapies for CRMO. In addition to the services and models listed above, we also provide customized services and disease model development services to meet your specific needs. If you are interested in our services, please don't hesitate to contact us.
Reference
- Singhal S., et al. "Classification and management strategies for paediatric chronic nonbacterial osteomyelitis and chronic recurrent multifocal osteomyelitis." Expert review of clinical immunology 19.9 (2023): 1101-1116.